RxDoctor Payments Data

Jimmy Wolfe, MD

Neurology · Jackson, MSNPI 1093791220

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.9% of the total across 806 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations.

$17,258in general payments, 2019–2025

Across 806 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Livanova USA, Inc.$1K
  • SK Life Science, Inc.$954
  • Teva Pharmaceuticals USA, Inc.$841
  • Pfizer$790
  • MDD US Operations, LLC$777
  • plus $11K from 53 others

What the payments were for

  • Speaking & faculty fees$1491%
  • Travel & lodging$8865%
  • Food & beverage$16,20694%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)108$1,748
Livanova USA, Inc.4$1,292
SK Life Science, Inc.47$954
Teva Pharmaceuticals USA, Inc.49$841
Pfizer39$790
MDD US Operations, LLC21$777
Lundbeck LLC39$750
Acadia Pharmaceuticals Inc30$639
Sanofi31$613
UCB, Inc.30$607
Amgen(2 entities)27$510
AstraZeneca23$502
Acorda Therapeutics, Inc20$434
Neurocrine Biosciences, Inc.20$432
Lilly USA, LLC28$404
Biogen19$395
Avanir Pharmaceuticals, Inc.18$382
Biohaven Pharmaceutical Holding Company Ltd.20$379
Biohaven Pharmaceuticals, Inc.22$355
Argenx US, Inc.11$349
Impel Pharmaceuticals Inc.18$337
Otsuka America Pharmaceutical, Inc.11$324
Eisai Inc.11$260
Merz Pharmaceuticals, LLC9$249
Sunovion Pharmaceuticals Inc.15$225
Novartis9$213
Genentech USA, Inc.17$212
Amneal Pharmaceuticals LLC11$195
CSL Behring8$190
EMD Serono, Inc.12$183
Supernus Pharmaceuticals, Inc.7$177
Sumitomo Pharma America, Inc.6$140
Takeda Pharmaceuticals U.S.A., Inc.6$135
Catalyst Pharmaceuticals, Inc.6$132
Mallinckrodt Hospital Products Inc.4$103
Neurelis, Inc.4$103
Upsher-smith Laboratories LLC6$101
Corium, LLC6$83
Amylyx Pharmaceuticals, Inc.3$75
Johnson & Johnson(2 entities)3$57
Greenwich Biosciences, Inc.3$55
Bristol Myers Squibb3$50
Jazz Pharmaceuticals Inc.2$49
Assertio Therapeutics, Inc.3$44
Abbott2$39
Philips North America LLC1$37
Sanofi-aventis U.S. LLC2$34
Ipsen Biopharmaceuticals, Inc1$34
Mylan Specialty L.p.1$33
GE HealthCare1$33
Convatec Inc.1$30
Kyowa Kirin, Inc.1$28
Si-bone, Inc.1$24
Xeris Pharmaceuticals, Inc.1$22
Axsome Therapeutics, Inc.1$20
Boston Scientific1$20
Medtronic1$20
Adamas Pharmaceuticals, Inc.1$20
ANI Pharmaceuticals, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,258 in reported general payments places this provider in the 75th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$51,473
Medicare patients
314
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LamictalLamotrigine14$19,967
UbrelvyUbrogepant13$18,552
XcopriCenobamate22$16,544
VimpatLacosamide11$13,003
Lacosamide51$5,665
Levetiracetam136$4,601
Oxcarbazepine41$2,393
Gabapentin99$1,752
Duloxetine Hcl99$1,707
Carbidopa-LevodopaCarbidopa/Levodopa102$1,540
Memantine Hcl61$1,519
Pregabalin22$1,361
Divalproex Sodium ErDivalproex Sodium29$939
Donepezil Hcl91$816
Baclofen12$662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,748$18,55213 claims
SK Life Science, Inc.Xcopri$954$16,54422 claims
UCB, Inc.Vimpat$607$13,00311 claims
Upsher-smith Laboratories LLCTopiramate$101$43457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 neurology providers in Mississippi.

Other neurology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →